A Phase 2 interventional study of MT-1303 in Crohn's Disease, sponsored by Mitsubishi Tanabe Pharma Corporation. Completed at 11 sites in 11 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2017-09-05.
Sponsored by Mitsubishi Tanabe Pharma Corporation · Phase 2, Interventional, and Treatment
The primary objectives of the study are:
-To evaluate the long-term safety and tolerability of MT-1303 in subjects with moderate to severe active Crohn's Disease（CD）
1,880 studies on the registry are indexed under Crohn Disease; 462 are open to participants now.
This study's enrollment of 46 is below the median of 66 across 1,188 interventional studies indexed under Crohn Disease.
Browse Crohn Disease studies →Mitsubishi Tanabe Pharma Corporation is the lead sponsor of 40 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Drug: MT-1303
Number of Subjects with Adverse Events
Time frame: 36 weeks
This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Mitsubishi Tanabe Pharma Corporation